Charles Theuer | executive |
Scott Brown | executive |
Edward White | analyst |
Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call. [Operator Instructions] During today's call, we will be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, financing opportunities, future expenses and cash runway into 2024, our development plans and strategy, potential cost savings deliverable through our product development platform or PDP, ability to enter into additional licensing agreements and expectations regarding the envafolimab treatment continuing to generate a double-digit objective response rates. These statements are subject to various risks that are described in our filings made with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2022, and subsequently, quarterly reports on Form 10-Q.
You are cautioned not to place undue reliance on these forward-looking statements. And unless required by applicable law, we disclaim any obligation to update such statements.